WHO Lists Antibiotic Development Priorities

The World Health Organization outlines critical-, high-, and medium-priority antibiotic development initiatives, calling on the public and private sectors to invest in additional R&D.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Scanning electron micrograph of a highly magnified cluster of Gram-negative, non-motile Acinetobacter baumannii bacteriaWIKIMEDIA, CDC

Update (March 13): In an open letter published last week (March 6), members of the Stop TB Partnership wrote that the WHO’s decision to leave Mycobacterium tuberculosis off its list of antibiotic development priorities sent “the false and counterproductive message that drug-resistant TB is not a public health threat.” Separately, José Luis Castro of the International Union Against Tuberculosis and Lung Disease wrote in an opinion for STAT News that “the exclusion of TB from the global priority list is a sudden broadside to the TB effort.” In response, WHO’s Kieny reiterated that the exclusion of TB was intentional. “The goal of this report is to highlight research and development needs in addition to, and beyond, those directed toward antibiotic-resistant TB,” Kieny wrote.

The World ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies